NASDAQ:DRNA

Dicerna Pharmaceuticals News Headlines

$26.04
-0.05 (-0.19 %)
(As of 04/12/2021 02:21 PM ET)
Add
Compare
Today's Range
$24.70
Now: $26.04
$26.36
50-Day Range
$22.91
MA: $26.58
$29.51
52-Week Range
$16.50
Now: $26.04
$29.90
Volume23,739 shs
Average Volume826,527 shs
Market Capitalization$1.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Headlines

Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines Today

SourceHeadline
-$0.28 Earnings Per Share Expected for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) This Quarter-$0.28 Earnings Per Share Expected for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) This Quarter
americanbankingnews.com - April 12 at 10:28 AM
Royalty Pharma Buys Dicernas Royalty Interest In OXLUMORoyalty Pharma Buys Dicerna's Royalty Interest In OXLUMO
markets.businessinsider.com - April 8 at 9:02 AM
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 MillionRoyalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
finance.yahoo.com - April 8 at 9:02 AM
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Insider Regina M. Paglia Sells 4,431 SharesDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Insider Regina M. Paglia Sells 4,431 Shares
americanbankingnews.com - April 5 at 11:28 PM
Bob D. Brown Sells 8,312 Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) StockBob D. Brown Sells 8,312 Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Stock
americanbankingnews.com - April 5 at 10:42 PM
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Given Consensus Recommendation of "Buy" by AnalystsDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - April 1 at 10:32 AM
Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical StudiesDicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies
finance.yahoo.com - March 30 at 1:29 PM
Dicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual CongressDicerna to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonucleotide and Precision Therapeutics Virtual Congress
finance.yahoo.com - March 24 at 8:53 AM
First Week of May 21st Options Trading For Dicerna Pharmaceuticals (DRNA)First Week of May 21st Options Trading For Dicerna Pharmaceuticals (DRNA)
nasdaq.com - March 19 at 3:07 PM
Dicerna Pharmaceuticals (NASDAQ:DRNA) Stock Price Down 7.8%Dicerna Pharmaceuticals (NASDAQ:DRNA) Stock Price Down 7.8%
americanbankingnews.com - March 18 at 8:34 PM
Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021Dicerna to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on March 18, 2021
finance.yahoo.com - March 11 at 7:33 AM
What You Need To Know About Dicerna Pharmaceuticals, Inc.s (NASDAQ:DRNA) Investor CompositionWhat You Need To Know About Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) Investor Composition
finance.yahoo.com - March 7 at 12:21 PM
Dicerna and Roche start mid-stage Hepatitis B RG6346 trialDicerna and Roche start mid-stage Hepatitis B RG6346 trial
seekingalpha.com - March 5 at 1:01 PM
Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus InfectionDicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
finance.yahoo.com - March 4 at 11:57 AM
Recap: Dicerna Pharmaceuticals Q4 EarningsRecap: Dicerna Pharmaceuticals Q4 Earnings
finance.yahoo.com - February 25 at 11:55 PM
Dicerna Announces Full Year 2020 Financial Results and Provides a Business UpdateDicerna Announces Full Year 2020 Financial Results and Provides a Business Update
finance.yahoo.com - February 25 at 6:54 PM
Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021Dicerna to Report Full Year 2020 Financial Results on Feb. 25, 2021
finance.yahoo.com - February 18 at 12:55 PM
Dicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage StudyDicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study
markets.businessinsider.com - February 11 at 1:50 PM
Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3Dicerna Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
finance.yahoo.com - February 11 at 8:49 AM
Novo Nordisk selects first development candidate under Dicerna pactNovo Nordisk selects first development candidate under Dicerna pact
seekingalpha.com - January 7 at 3:15 PM
Should You Take Comfort From Insider Transactions At Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)?Should You Take Comfort From Insider Transactions At Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)?
finance.yahoo.com - January 6 at 1:11 PM
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone AchievementDicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
finance.yahoo.com - January 5 at 9:26 AM
Is the Options Market Predicting a Spike in Dicerna (DRNA) Stock?Is the Options Market Predicting a Spike in Dicerna (DRNA) Stock?
finance.yahoo.com - December 22 at 2:46 PM
Is DRNA A Good Stock To Buy Now According To Hedge Funds?Is DRNA A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 20 at 5:05 PM
First Week of DRNA February 2021 Options TradingFirst Week of DRNA February 2021 Options Trading
nasdaq.com - December 18 at 3:12 PM
Dicerna: Great Value RNAi Runner UpDicerna: Great Value RNAi Runner Up
seekingalpha.com - December 17 at 8:46 AM
Is Dicerna Pharmaceuticals (DRNA) a Smart Long-term Buy?Is Dicerna Pharmaceuticals (DRNA) a Smart Long-term Buy?
finance.yahoo.com - December 11 at 1:30 PM
Dicerna Pharmaceuticals Inc OutperformDicerna Pharmaceuticals Inc Outperform
markets.businessinsider.com - November 27 at 12:29 AM
Dicerna/Roches hepatitis B candidate shows durable effect in early-stage studyDicerna/Roche's hepatitis B candidate shows durable effect in early-stage study
seekingalpha.com - November 16 at 6:40 PM
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting ® Digital ...Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting ® Digital ...
businesswire.com - November 16 at 1:39 PM
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and ...Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and ...
businesswire.com - November 16 at 8:38 AM
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing AgreementDicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
finance.yahoo.com - November 16 at 8:38 AM
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
finance.yahoo.com - November 16 at 8:38 AM
Dicerna to Participate in Upcoming Investor ConferencesDicerna to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 11 at 8:22 PM
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
finance.yahoo.com - November 10 at 6:40 PM
Was The Smart Money Wrong About Piling Into Dicerna Pharmaceuticals Inc (DRNA)?Was The Smart Money Wrong About Piling Into Dicerna Pharmaceuticals Inc (DRNA)?
finance.yahoo.com - November 9 at 5:33 PM
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
nasdaq.com - November 7 at 1:04 PM
Earnings Update: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Just Reported And Analysts Are Boosting Their EstimatesEarnings Update: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Just Reported And Analysts Are Boosting Their Estimates
finance.yahoo.com - November 7 at 1:04 PM
Dicerna Pharmaceuticals Inc (DRNA) Q3 2020 Earnings Call TranscriptDicerna Pharmaceuticals Inc (DRNA) Q3 2020 Earnings Call Transcript
finance.yahoo.com - November 6 at 2:37 PM
Dicerna Pharmaceuticals EPS misses by $0.05, misses on revenueDicerna Pharmaceuticals EPS misses by $0.05, misses on revenue
seekingalpha.com - November 5 at 6:31 PM
Dicerna Pharmaceuticals, Inc. to Host Earnings CallDicerna Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 5 at 6:31 PM
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business UpdateDicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
finance.yahoo.com - November 5 at 6:31 PM
Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020
finance.yahoo.com - November 1 at 5:02 PM
Will Dicerna Pharmaceuticals (DRNA) Report Negative Q3 Earnings? What You Should KnowWill Dicerna Pharmaceuticals (DRNA) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - October 29 at 6:07 PM
Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020
finance.yahoo.com - October 29 at 6:07 PM
Dicernas nedosiran shows positive effect in rare kidney stone disorderDicerna's nedosiran shows positive effect in rare kidney stone disorder
seekingalpha.com - October 22 at 12:42 PM
Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)
finance.yahoo.com - October 22 at 12:42 PM
Dicerna Appoints Ling Zeng as Chief Legal Officer and SecretaryDicerna Appoints Ling Zeng as Chief Legal Officer and Secretary
finance.yahoo.com - September 16 at 10:34 AM
Dicerna Pharmaceuticals Inc (DRNA) President and CEO Douglas Fambrough Bought $180,600 of SharesDicerna Pharmaceuticals Inc (DRNA) President and CEO Douglas Fambrough Bought $180,600 of Shares
finance.yahoo.com - September 2 at 12:36 AM
Dicernas hepatitis B drug shows encouraging effect in early-stage studyDicerna's hepatitis B drug shows encouraging effect in early-stage study
seekingalpha.com - August 6 at 5:24 PM
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.